Literature DB >> 32969124

Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy.

Yuzo Suzuki1, Yuya Aono1, Masato Kono2, Hirotsugu Hasegawa3, Koushi Yokomura3, Hyogo Naoi1, Hironao Hozumi1, Masato Karayama1, Kazuki Furuhashi1, Noriyuki Enomoto1, Tomoyuki Fujisawa1, Yutaro Nakamura1, Naoki Inui1, Hidenori Nakamura2, Takafumi Suda1.   

Abstract

BACKGROUND AND
OBJECTIVE: Recent research has highlighted the fundamental role of sarcopenia, characterized by loss of skeletal muscle mass and strength, with a risk of poor outcomes. AFT preserves lung function by preventing the annual decline in FVC and is associated with improved outcomes in patients with IPF. However, altered cause of death and prognostic implications of sarcopenia in patients with IPF receiving AFT remain unknown.
METHODS: This study comprised two cohorts of patients with IPF receiving AFT, historical cohort of IPF patients without AFT and controls. The cause of mortality was compared with a historical cohort. Sarcopenia was assessed by measuring the ESMCSA and ESMMA via CT.
RESULTS: Patients with IPF had smaller ESMCSA and lower ESMMA but similar BMI than controls, suggesting patients with IPF had skeletal muscle loss without any obvious body weight loss. The most common cause of mortality in patients receiving AFT was chronic respiratory failure, accounting for approximately 60%, and decreased proportions of LC were found. Subsequently, low ESMCSA was an independent prognostic factor associated with worse survival rates. Furthermore, combined assessment of ESMCSA , %FVC predicted and BMI values provided clear prognostic distinction.
CONCLUSION: Patients with IPF receiving AFT showed skeletal muscle loss without obvious weight loss. These patients mostly died by chronic respiratory failure, and skeletal muscle wasting has prognostic significance, suggesting that preventing sarcopenia as well as preserving lung function are important for managing these patients.
© 2020 Asian Pacific Society of Respirology.

Entities:  

Keywords:  antifibrotic therapy; idiopathic pulmonary fibrosis; sarcopenia; skeletal muscle loss

Mesh:

Year:  2020        PMID: 32969124     DOI: 10.1111/resp.13943

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  9 in total

1.  Decreased peak expiratory flow rate associated with mortality in idiopathic pulmonary fibrosis: A preliminary report.

Authors:  Kohei Fujita; Hirotsugu Ohkubo; Akiko Nakano; Norihisa Takeda; Kensuke Fukumitsu; Satoshi Fukuda; Yoshihiro Kanemitsu; Takehiro Uemura; Tomoko Tajiri; Ken Maeno; Yutaka Ito; Tetsuya Oguri; Yoshiyuki Ozawa; Takayuki Murase; Akio Niimi
Journal:  Chron Respir Dis       Date:  2022 Jan-Dec       Impact factor: 3.115

2.  Standardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis.

Authors:  Yuko Tanaka; Yuzo Suzuki; Hirotsugu Hasegawa; Koshi Yokomura; Atsuki Fukada; Yusuke Inoue; Hironao Hozumi; Masato Karayama; Kazuki Furuhashi; Noriyuki Enomoto; Tomoyuki Fujisawa; Yutaro Nakamura; Naoki Inui; Takafumi Suda
Journal:  Respir Res       Date:  2022-06-01

3.  Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study.

Authors:  Paola Faverio; Alessia Fumagalli; Sara Conti; Fabiana Madotto; Francesco Bini; Sergio Harari; Michele Mondoni; Tiberio Oggionni; Emanuela Barisione; Paolo Ceruti; Maria Chiara Papetti; Bruno Dino Bodini; Antonella Caminati; Angela Valentino; Stefano Centanni; Donatella Noè; Matteo Della Zoppa; Silvia Crotti; Marco Grosso; Samir Giuseppe Sukkar; Denise Modina; Marco Andreoli; Roberta Nicali; Giulia Suigo; Federica De Giacomi; Sara Busnelli; Elena Cattaneo; Lorenzo Giovanni Mantovani; Giancarlo Cesana; Alberto Pesci; Fabrizio Luppi
Journal:  ERJ Open Res       Date:  2022-03-07

4.  Impact of sarcopenia on chemotherapy-triggered exacerbation of interstitial lung disease in patients with non-small cell lung cancer.

Authors:  Ryota Kikuchi; Hiroyuki Takoi; Mayuko Ishiwari; Kazutoshi Toriyama; Yuta Kono; Yuki Togashi; Shinji Abe
Journal:  Thorac Cancer       Date:  2021-12-28       Impact factor: 3.500

Review 5.  Idiopathic pulmonary fibrosis: Current and future treatment.

Authors:  Daniel S Glass; David Grossfeld; Heather A Renna; Priya Agarwala; Peter Spiegler; Joshua DeLeon; Allison B Reiss
Journal:  Clin Respir J       Date:  2022-01-10       Impact factor: 1.761

6.  Frequency and impact on clinical outcomes of sarcopenia in patients with idiopathic pulmonary fibrosis.

Authors:  Kohei Fujita; Hirotsugu Ohkubo; Akiko Nakano; Yuta Mori; Kensuke Fukumitsu; Satoshi Fukuda; Yoshihiro Kanemitsu; Takehiro Uemura; Tomoko Tajiri; Ken Maeno; Yutaka Ito; Tetsuya Oguri; Yoshiyuki Ozawa; Takayuki Murase; Akio Niimi
Journal:  Chron Respir Dis       Date:  2022 Jan-Dec       Impact factor: 3.115

Review 7.  Contemporary Concise Review 2021: Interstitial lung disease.

Authors:  Cormac McCarthy; Michael P Keane
Journal:  Respirology       Date:  2022-05-05       Impact factor: 6.175

8.  Sarcopenia in idiopathic pulmonary fibrosis: a prospective study exploring prevalence, associated factors and diagnostic approach.

Authors:  Paola Faverio; Alessia Fumagalli; Sara Conti; Fabiana Madotto; Francesco Bini; Sergio Harari; Michele Mondoni; Tiberio Oggionni; Emanuela Barisione; Paolo Ceruti; Maria Chiara Papetti; Bruno Dino Bodini; Antonella Caminati; Angela Valentino; Stefano Centanni; Paola Lanzi; Matteo Della Zoppa; Silvia Crotti; Marco Grosso; Samir Giuseppe Sukkar; Denise Modina; Marco Andreoli; Roberta Nicali; Giulia Suigo; Sara Busnelli; Giuseppe Paciocco; Sara Lettieri; Lorenzo Giovanni Mantovani; Giancarlo Cesana; Alberto Pesci; Fabrizio Luppi
Journal:  Respir Res       Date:  2022-09-03

9.  Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.

Authors:  Yuzo Suzuki; Kazutaka Mori; Yuya Aono; Masato Kono; Hirotsugu Hasegawa; Koshi Yokomura; Hyogo Naoi; Hironao Hozumi; Masato Karayama; Kazuki Furuhashi; Noriyuki Enomoto; Tomoyuki Fujisawa; Yutaro Nakamura; Naoki Inui; Hidenori Nakamura; Takafumi Suda
Journal:  BMC Pulm Med       Date:  2021-07-12       Impact factor: 3.317

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.